Therefore, we hypothesized that the inhibition of AURKA may be beneficial to the treatment of DLBCL by CHOP and verified whether silencing AURKA can enhance the therapeutic effect of CHOP therapy on DLBCL by regulating β-catenin and RAS-ERK1/2 pathway in vitro. The gene discussed is AURKA; the disease is diffuse large B-cell lymphoma.